Breathe Well Live Well
|
Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In …
RTT News Array BioPharma Inc. (ARRY: Quote) announced positive results from a placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist. ARRY-502 achieved the primary … |
View full post on asthma – Google News
|
Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung …
Wall Street Journal Secondary efficacy endpoints in the proof-of-concept study were also achieved, including reduced short-acting beta agonist use; asthma control; forced vital capacity improvement; symptom-free days during treatment; and improvement in rhinasthma and … Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In … Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial |
View full post on asthma – Google News
|
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
PR Newswire (press release) BOULDER, Colo., July 23, 2013 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced positive results from a placebo-controlled, randomized, double?blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, … Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial After-market Movers For July 22 (NFLX, TXN, SANM, ARRY) |
View full post on asthma – Google News
|
Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
Benzinga Array BioPharma Inc. (Nasdaq: ARRY) will report top-line results from a placebo-controlled, randomized, double?blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to … |
View full post on asthma – Google News